(Total Views: 572)
Posted On: 10/07/2021 11:49:00 AM
Post# of 72433
![Avatar](https://investorshangout.com/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
BMY's ulcerative colitis drug fails clinical trials. If only we knew of a company that had an anti-inflammatory, antibiotic drug that might help diseases of the gut.....
Quote:
Bristol Myers Squibb’s deucravacitinib, seeking to become the first TYK2 drug approved, flopped a key Phase II test in ulcerative colitis, failing to spur clinical remission at three months and missing key secondary endpoints at an interim check-in, the drug giant admitted Thursday.
https://endpts.com/bristol-myers-tyk2-drug-bo...g-on-deck/
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)